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Conclusions: In this work, we evaluated 6 atlas fusion methods for 
automated segmentation of lymph nodes in the 3-D head and neck CT 
images. Among all the methods, our recently proposed Markov 
Random Field (MRF) based fusion method that performs 
simultaneously both local weighted voting based fusion and smoothing 
(LWV+MRF) provided the best results, both in terms of overlap 
measure and contiguous regions. 
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Purpose/Objective: Delineation of esophageal tumours for 
radiotherapy treatment planning is currently done on CT images. 
Differentiating healthy tissue from tumour on CT is difficult due to 
poor soft tissue contrast. Thus, tumour delineation is predominantly 
based on identifying esophageal wall thickening. Determination of the 
tumour extent in the cranio-caudal (CC) direction remains particularly 
challenging. MRI with its various sequences can provide both 
anatomical and functional information. Diffusion-weighted MRI (DW-
MRI) makes it possible to identify areas with restricted diffusion, 
which occurs in many primary and metastatic tumors. This additional 
information may help to improve delineation of the treatment 
volume. The aim of this study is to assess the potential benefit of DW-
MRI in GTV delineation of esophageal tumours. 
Materials and Methods: Seven patients with esophageal cancer 
underwent a planning CT and an MRI scan. Scans were acquired within 
one week of each other. The MRI scan was performed on a 1.5T 
scanner and consisted of a diffusion-weighted MRI sequence (b = 800 
s/mm2) and T2w scans. Two physicians independently defined the GTV 
for each tumour: first on the CT images and then on the MR-images. 
The T2w images were used as anatomical images and were co-
registered to the DW-MRI scan. Consensus on the definition of CC 
tumour borders was evaluated by measuring the absolute difference 
between the delineations. Furthermore, inter-observer agreement 
was assessed using the conformity index (CI), defined as the ratio of 
common to encompassing volume. 
Results: The DW-MR images clearly showed areas of high contrast in 
the tumor region (fig. 1). Consequently the consensus on defining the 
caudal tumour border improved in 6 out of 7 patients when delineated 
on DW-MRI compared to CT. The median absolute difference between 
observers was 7mm on CT as opposed to 4mm on DW-MRI. Six out of 7 
caudal tumour borders were located near the gastro-esophageal 
junction (GEJ). Tumor delineation in this area is especially challenging 
with the CT-based delineations currently used in clinical practice. No 
difference was found in agreement on the cranial tumour border, with 
a median difference of 4mm between observers on both modalities. 
Delineations showed negligible disagreement in the transversal plane. 
This was also reflected in similar volumes delineated on CT and DW-
MRI (median: 59.7 vs. 58.3cm3). In this study with a small number of 
patients, the median CI showed no clear difference between 
modalities (CT: 0.77, range: 0.68-0.79 vs. DW-MRI: 0.75,range: 0.54-
0.84). However, an improvement in CI was seen in 5 out of 7patients 
on the DW-MRI based delineation. 
 
 
Conclusions: DW-MRI shows excellent contrast in esophageal tumours 
and consequently may be useful for esophageal tumour delineation. In 
comparison to CT-based delineations, our results demonstrate that 
DW-MRI is promising in defining tumour extent in the CC direction, 
especially in the caudal borders near the GEJ.  
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Purpose/Objective: In vivo dosimetry for intraoperative electron 
radiation therapy (IOERT) is challenging because of the non-reference 
conditions of the irradiated area. However, in vivo dosimetry is 
desirable for verification, recording and eventual correction of 
treatment. MOSFETs and radiochromic films have been used for these 
purposes, chiefly in breast treatments. The aim of our work is to share 
our first analysis on tumor bed absorbed dose evaluation regardless of 
its localization and begin a discussion on an action level (AL) for all 
treatments in general. 
Materials and Methods: Reinforced mobile MOSFETs model TN-
502RDM-H and Gafchromic MD-55-2 film were used. MOSFETs 
calibration involved a linear relationship between dose and voltage 
difference before and after irradiation. With regard to film 
calibration, polynomial fitting of the absorbed doses to the mean pixel 
values was performed. Associated uncertainties were also estimated. 
A general purpose LINAC was used for calibrations and treatments. 
Measurement uncertainties were assessed for both methods. 
Measurements were taken from 14 patients: 9 primary tumors (4 
rectal tumors, 2 breast, 1 abdominal sarcoma, 1 scapular sarcoma and 
1 lower limb skin tumor) and 5 relapses (3 presacral, 1 nodal and 1 
pancreatic recurrence) involving 15 pairs of measurements in total at 
the tumor bed. All data were normalized so that 100% corresponded to 
the maximum absorbed dose.  
Afterwards, two approaches to reviewing or compensating treatment 
involving AL were derived. They are formally equivalent, since AL = 
2u. In the first approach, u represents the uncertainty of a single 
measurement. However, in the second, u represents the mean 
standard error (MSE) of a series of measurements. AL should be added 
to the intended absorbed doses interval (e.g. 90%-100%). 
Results: The three identified sources of uncertainty of the measured 
absorbed dose were those associated with beam calibration, equal to 
0.4%, lack of linearity of linac output (e.g. 0.03 Gy in a typical 3000 
MU treatment) and detector response, totalling 1.7% in the case of 
MOSFETs and 2.4% in the case of films (1 SD). 
Descriptive statistics of our data are depicted in table 1. The two 
distributions (fig. 1) did not appear as significantly shifted when 
subjected to the Wilcoxon signed ranks test (p = 0.363). 
 
 
  
